Skip to main content

Advertisement

Table 3 Incidence rate ratios of 842 breast cancer patients followed by thyroid cancer, stratified by factors

From: Clinicopathological features, survival and risk in breast cancer survivors with thyroid cancer: an analysis of the SEER database

VariableTotal6–36 months> 36 months
ObservedSIRCI lowCI highExcess riskObservedSIRCI lowCI highObservedSIRCI lowCI high
Race
 White6601.15*1.061.240.372631.67**1.471.883970.950.861.05
 Black771.88**1.482.341.61322.63**1.803.71451.56*1.142.09
 Asian or Pacific Islander971.46*1.181.781.19432.19*1.592.95541.150.871.51
Site
 Central portion551.48*1.121.931.13282.76**1.843.99271.000.661.45
 Upper-inner901.230.991.510.56321.53*1.052.16581.110.841.43
 Lower-inner441.200.871.620.49171.640.962.63271.030.681.50
 Upper-outer3011.19*1.061.330.461121.65*1.361.981891.020.881.18
 Lower-outer561.200.911.560.50201.500.922.32361.080.761.50
 Overlapping lesion1671.19*1.021.390.48822.04**1.632.54850.850.681.05
Grade
 11361.120.941.330.31451.260.921.68911.070.861.31
 23501.27*1.141.410.661341.72*1.442.042161.090.951.25
 32831.30*1.161.470.761352.16**1.812.561480.960.811.12
ER
 Positive6011.24*1.141.340.592421.71*1.501.943591.040.941.16
 Negative1551.25*1.061.470.63722.10**1.652.65830.930.741.15
PR
 Positive5321.27*1.171.390.682161.79**1.562.043161.060.951.19
 Negative2021.150.991.320.36921.78**1.442.191100.880.711.06
ER (+) PR (+)5071.26*1.151.370.642061.75**1.522.013011.050.941.18
ER (−) PR (−)1251.160.961.380.40611.97*1.512.53640.830.641.06
  1. SIR Standardized incidence ratio, CI Confidence interval, ER Estrogen receptor, PR Progesterone receptor
  2. *p < 0.05; **p < 0.01